Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose

Blood

Volumn 91, Issue 12, 1998, Pages 4464-4471

  Römer, Wolfgang ^a   Hanauske, Axel R ^b   Ziegler, Sibylle ^b   Thödtmann, Ralf ^b   Weber, Wolfgang ^b   Fuchs, Christoph ^b   Enne, Wolfgang ^b   Herz, Michael ^b   Nerl, Christoph ^b   Garbrecht, Manfred ^b   Schwaiger, Markus ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; MITOGUAZONE; PREDNISOLONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG MONITORING; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE UTILIZATION; HUMAN; MALE; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ASSAY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG MONITORING; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 2642613656     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Warburg O: The metabolism of tumors. London, UK, Constable, 1930
2. Fischman AJ, Alpert NM: FDG-PET in oncology: There's more to it than looking at pictures. J Nucl Med 34:6, 1993
3. Strauss LG, Conti PS: The applications of PET in clinical oncology. J Nucl Med 32:623, 1991
4. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, Benoit T, Foidart WJ: Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 23:1641, 1996
5. Minn H, Paul R, Ahonen A: Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. J Nucl Med 29:1521, 1988
6. Minn H, Soini I: F-18-fluordeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Eur J Nucl Med 15:61, 1989
7. Haberkorn U, Strauss LG, Dimitrakopoulou A, Engenhart R, Oberdorfer F, Ostertag H, Romahn J, van Kaick G: PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 32:1485, 1991
8. Ichiya Y, Kuwabara Y, Otsuka M, Tahara T, Yoshikai T, Fukumura T, Jingu K, Masuda K: Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. J Nucl Med 32:1655, 1991
9. Bassa P, Kim EE, Inoue T, Wong FCL, Korkmaz M, Yang DJ, Won W-H, Hicks KW, Buzdar AU, Podoloff DA: Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 37:931, 1996
10. Jones DN, McCowage GB, Sostman HD, Brizel DM, Layfield L, Charles HC, Dewhirst MW, Prescott DM, Friedman HS, Harrelson JM, Scully SP, Coleman RE: Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. J Nucl Med 37:1438, 1996
11. Haberkorn U, Morr I, Oberdorfer F, Bellemann ME, Blatter J, Altmann A, Kahn B, van Kaick G: Fluorodeoxyglucose uptake in vitro: Aspects of method and effects of treatment with gemcitabine. J Nucl Med 35:1842, 1994
12. Schaider H, Haberkorn U, Berger MR, Oberdorfer F, Morr I, van Kaick G: Application of alpha-aminoisobutyric acid, L-methionine, thymidine and 2-fluoro-2-deoxy-D-gIucose to monitor effects of chemotherapy in a human colon carcinoma cell line. Eur J Nucl Med 23:55, 1996
13. Higashi K, Clavo AC, Wahl RL: In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. J Nucl Med 34:773, 1993
14. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R: Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation. J Clin Oncol 11:2101, 1993
15. Jansson T, Westlin JE, Ahlstrom H, Lilja A, Langstrom B, Bergh J: Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: A method for early therapy evaluation? J Clin Oncol 13:1470, 1995
16. Lapela M, Leskinen S, Minn HR, Lindholm P, Klemi PJ, Soderstrom KO, Bergman J, Haaparanta M, Ruotsalainen U, Solin O, Joensuu H: Increased glucose metabolism in untreated non-Hodgkin's lymphoma: A study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 86:3522, 1995
17. Dung J, Fiedler W, de Wit M, Steffen M, Hossfeld DK: Lactic acidosis and hypoglycemia in a patient with high-grade non-Hodgkin's lymphoma and elevated circulating TNF-alpha. Ann Hematol 72:97, 1996
18. Dimitrakopoulou-Strauss A, Strauss LG, Goldschmidt H, Lorenz WJ, Maier BW, van Kaick G: Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas. Eur J Nucl Med 22:434, 1995
19. Leskinen KS, Ruotsalainen U, Nagren K, Teras M, Joensuu H: Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: A PET study. J Nucl Med 32:1211, 1991
20. Lindholm P, Leskinen KS, Minn H, Bergman J, Haaparanta M, Lehikoinen P, Nagren K, Ruotsalainen U, Teras M, Joensuu H: Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine in head and neck cancer. J Nucl Med 34:1711, 1993
21. Hoekstra OS, Ossenkoppele GJ, Golding R, van Lingen A, Visser GW, Teule GJ, Huijgens PC: Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxy-glucose scintigraphy. J Nucl Med 34:1706, 1993
22. Hoekstra OS, van Lingen A, Ossenkoppele GJ, Golding R, Teule GJ: Early response monitoring in malignant lymphoma using fluorine-18 fluorodeoxyglucose single-photon emission tomography. Eur J Nucl Med 20:1214, 1993
23. Rodriguez M, Rehn S, Ahlstrom H, Sundstrom C, Glimelius B: Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med 36:1790, 1995
24. Llanos M, Tabernero J, Brunei J, Amenedo M, Pallares C, de Andres L, Lopez JJ: CHOP chemotherapy of intermediate and highgrade non-Hodgkin's lymphoma. Acta Oncol 33:935, 1994
25. Meyer RM, Browman GP, Samosh ML, Benger AM, Bryant LD, Wilson WE, Frank GL, Leber BF, Sternbach MS, Foster GA: Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol 13:2386, 1995
26. Stansfeld AG, Diebold J, Noel H, Kapanci Y, Rilke F, Kelényi G, Sundströrn C, Lennert K, van Unnik JAM, Mioduszewska O, Wright DH: Updated Kiel classification for lymphomas. Lancet 1:292, 1988
27. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CJ, Miller TP: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002, 1993
28. Hamacher K, Coenen HH, Stöcklin G: Efficient stereo specific synthesis of nocarrier-added 2-(F-18)-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 27: 235, 1986
29. Patlak CS, Blasberg RG: Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 3:1, 1983
30. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207, 1981
31. Iosilevsky G, Front D, Bettman L, Hardoff R, Ben-Arieh Y: Uptake of Gallium-67 citrate and 2-3H deoxyglucose in the tumor model, following chemotherapy and radiotherapy. J Nucl Med 26:278, 1985
32. Abe Y, Matsuzawa T, Fujiwara T, Fukuda H, Itoh M, Yamada K, Yamaguchi K, Sato T, Ido T: Assessment of radiotherapeutic effects on experimental tumors using F-18-2-fluoro-2-deoxy-D-glucose. Eur J Nucl Med 12:325, 1986
33. Kubota K, Ishiwata K, Kubota R, Yamada S, Tada M, Sato T, Ido T: Tracer feasibility for monitoring tumor radiotherapy: A quadruple tracer study with fluorine-18-fluorodeoxyglucose or fluorine-18-fluorodeoxyuridine, L-[methyl-14C]methionine, [6-3H]thymidine, and gallium-67. J Nucl Med 32:2118, 1991
34. Fisher RI: Treatment of aggressive non-Hodgkin' lymphomas. Lessons from the past 10 years. Cancer 74:2657, 1994
35. Weber W, Thödtmann R, Ziegler S, Römer W, Hanauske A, Schwaiger M: Reproducibility of FDG-PET in malignant tumors. J Nucl Med 38:243, 1997
36. Minn H, Zasadny KR, Quint LE, Wahl RL: Lung cancer: Reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology 196:167, 1995
37. Lindholm P, Minn H, Leskinen KS, Bergman J, Ruotsalainen U, Joensuu H: Influence of the blood glucose concentration on FDG uptake in cancer-a PET study. J Nucl Med 34:1, 1993
38. Langen KJ, Braun U, Rota KE, Herzog H, Kuwert T, Nebeling B, Feinendegen LE: The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med 34:355, 1993
39. Canellos GP: Residual mass in lymphoma may not be residual disease. J Clin Oncol 6:931, 1988
40. Thomas F, Cosset JM, Cherel P, Renaudy N, Carde P, Piekarski JD: Thoracic CT-scanning follow-up of residual mediastinal masses after treatment of Hodgkin's disease. Radiother Oncol 11:119, 1988
41. Avril N, Dose J, Jänicke F, Bense S, Ziegler S, Laubenbacher C, Römer W, Fache H, Herz M, Allgayer B, Nathrath W, Graeff H, Schwaiger M: Metabolie characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 14:1848, 1996
42. Janicek M, Kaplan W, Neuberg D, Canellos GP, Shulman LN, Shipp MA: Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy. J Clin Oncol 15:1631, 1997
43. Bartold SP, Donohoe KJ, Fletcher JW, Haynie TP, Henkin RE, Silberstein EB, Royal HD, Van den Abbeele A: Procedure guideline for gallium scintigraphy in the evaluation of malignant disease. J Nucl Med 38:990, 1997
44. Armitage JO, Vose JM, Bierman PJ, Bishop MR: Salvage therapy for patients with lymphoma. Semin Oncol 21:82, 1994
45. Vose JM, Armitage JO: What is the role of third generation regimens for initial therapy of non-Hodgkin's lymphomas? Leuk Lymphoma 10:61, 1993
46. Hawkins RA, Choi Y, Huang S-C, Messa C. Hoh CK, Phelps ME: Quantitating tumor glucose metabolism with FDG and PET. J Nucl Med 33:339, 1992
47. Zasadny KR, Wahl RL: Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: Variations with body weight and a method for correction. Radiology 189:847, 1993
48. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ: The dose uptake ratio as an index of glucose metabolism: Useful parameter or oversimplification? J Nucl Med 35:1308, 1994